Filgotinib for moderate to severe polyarticular juvenile arthritis
Treatments studied
Part of Bones, joints & muscles, Immune system & allergy, Skin clinical trials.
This trial tests filgotinib, a new medication that may help reduce joint swelling and pain in children and teens (ages 8–17) with polyarticular juvenile idiopathic arthritis—a type of childhood arthritis affecting multiple joints. You're eligible if your current arthritis medicines haven't worked well enough.
Summary written for real people, not researchers, by Clin2.
Who can take part
- Your child is between 8 and 17 years old
- Diagnosed with polyarticular juvenile idiopathic arthritis (multiple-joint type) that is moderate to severe
- Current arthritis medicines have not worked well or caused problems for at least 3 months
- Your child weighs at least 15 kg (about 33 pounds)
- Willing to use contraception if female and sexually active
- No active eye inflammation (uveitis) in the past 12 weeks and no other serious rheumatic or immune diseases
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests if filgotinib, a pill for adults with ulcerative colitis, works in children and teenagers. It may help those whose current treatments are not working well enough or cause side effects.
This trial is testing a new drug (a JAK inhibitor) for people with rare inflammatory diseases like Behçet's, myositis, or IgG4-related disease that hasn't improved with standard treatments. The goal is to see if it can help control symptoms and reduce inflammation.
This study lets young people who benefited from filgotinib (a medication that reduces inflammation) in a previous trial continue taking it to see if it stays safe and effective over a longer period. It's designed for patients ages 8–17 who did well on this medicine before.
This Phase 4 study compares two treatment options for rheumatoid arthritis (RA): filgotinib or a TNF inhibitor (TNFi). It is designed for adults whose current “standard” RA tablets have not worked well or were not tolerated, to see which approach improves RA control.
This trial studies the use of a medication called tofacitinib in children and teenagers with juvenile idiopathic arthritis (JIA), a type of arthritis that starts in childhood. The goal is to see if the drug helps reduce joint pain and inflammation.
This Phase 3 trial studies how well upadacitinib (a pill) and tocilizumab (a shot/IV medicine) improve symptoms and inflammation in children with active systemic juvenile idiopathic arthritis (sJIA). It also looks at side effects and how these medicines move through the body.
Hear when a new Polyarticular Course Juvenile Idiopathic Arthritis trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.